RYBELSUS 7 MG — DIN 02497603
SEMAGLUTIDE : 7 MG · NOVO NORDISK CANADA INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is RYBELSUS?
RYBELSUS 7 MG contains SEMAGLUTIDE : 7 MG. It is listed in the Health Canada Drug Product Database under DIN 02497603, held by NOVO NORDISK CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 19-Apr-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is RYBELSUS used for?
RYBELSUS® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus: • as monotherapy when metformin is considered inappropriate due to intolerance or contraindications; • in combination with other medicinal products for the treatment of diabetes (see 14 CLINICAL TRIALS for patient populations and drug combinations tested). • to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or are at high risk for these events.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Semaglutide cost around the world?
Semaglutide is listed on 12 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 6 | 22 | SAR███.██ |
| Hungary | producer price (ex-factory) | 14 | 16 | HUF███.██ |
| Iceland | max wholesale | 5 | 16 | ISK███.██ |
| Luxembourg | reimbursement | 15 | 15 | EUR███.██ |
| United Arab Emirates | public | 12 | 14 | AED███.██ |
| Bahrain | retail (max) | 7 | 14 | BHD███.██ |
| Greece | producer price (ex-factory) | 12 | 12 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 2 | 11 | CZK███.██ |
| South Africa | single exit price | 8 | 11 | ZAR███.██ |
| Italy | prezzo al pubblico (classe A) | 9 | 10 | EUR███.██ |
| Australia | ex-manufacturer | 1 | 6 | AUD███.██ |
| Austria | KVP (Kassenverkaufspreis) | 4 | 4 | EUR███.██ |
151 pack listings across 95 brand entries and 10 price bases, refreshed 08 Sep 2026. Ranges span every Semaglutide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Semaglutide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
Only one market authorization holder has a Canadian DIN containing Semaglutide — 17 DINs, of which 9 are currently marketed. There is no second Canadian source today, so a supply interruption on this holder has no domestic substitute at the same molecule.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| NOVO NORDISK CANADA INC | 17 | 9 | OZEMPIC, RYBELSUS, WEGOVY | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 7 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Initial Formulation of Rybelsus® 3 mg, 7 mg and 14 mg tablets: 3 mg tablets: white to light yellow, oval shaped, debossed with “3” on one side and “novo” on the other side. Supplied in green coloured cartons containing alu/alu blisters in pack sizes of 30, 60 or 90 tablets. 7 mg tablets: white to light yellow, oval shaped, debossed with “7” on one side and “novo” on the other side. Supplied in red coloured cartons containing alu/alu blisters in pack sizes of 30, 60 or 90 tablets. 14 mg tablets: white to light yellow, oval shaped, debossed with “14” on one side and "novo" on the other side. Supplied in blue coloured cartons containing alu/alu blisters in pack sizes of 30, 60 or 90 tablets. Optimized Formulation of Rybelsus® 1.5 mg, 4 mg and 9 mg tablets: 1.5 mg tablets: white to light yellow, round shaped, debossed with “1.5” on one side and "novo" on the other side. Supplied in green coloured cartons containing alu/alu blisters in pack sizes of 30 tablets. 4 mg tablets: white to light yellow, round shaped, debossed with “4” on one side and "novo” on the other side. Supplied in red coloured cartons containing alu/alu blisters in pack sizes of 30 or 90 tablets. 9 mg tablets: white to light yellow, round shaped, debossed with “9” on one side and "novo" on the other side. Supplied in blue coloured cartons containing alu/alu blisters in pack sizes of 30 or 90 tablets. |
| Storage | Store at room temperature (15°C to 30°C) out of the reach of children. Rybelsus® must be stored in the original blister packaging to protect from moisture and light. Take the tablet directly after removing from blister card. Do not use after the expiry date. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Substance and classification
| Active substance | Semaglutide |
|---|---|
| ATC code | A10BJ06 |
| AHFS class | 68:20.06 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02497603 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2497603 |
| Brand name | RYBELSUS |
| Generic / active ingredient | SEMAGLUTIDE : 7 MG |
| Market authorization holder | NOVO NORDISK CANADA INC |
| Health Canada schedule | Schedule D |
| ATC code | A10BJ06 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A10BJ |
| Current status | MARKETED |
| Status date | 19-Apr-2020 |
| Original market date | 2020-04-19 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Do not take more than one tablet of Rybelsus® daily. Do not take two or more tablets of Rybelsus® to obtain a higher dose. Initial Formulation of Rybelsus® 3 mg, 7 mg, 14 mg tablets: The starting dose of Rybelsus® is 3 mg once daily. After 30 days, the dose should be increased to a maintenance dose of 7 mg once daily. If additional glycemic control is needed after at least 30 days on the 7 mg dose, the dose can be increased to a maintenance dose of 14 mg once daily. This regimen is intended to mitigate gastrointestinal symptoms during dose escalation. The maximum recommended single daily dose of oral semaglutide is 14 mg. Optimized Formulation of Rybelsus® 1.5 mg, 4 mg, 9 mg tablets: The starting dose of Rybelsus® is 1.5 mg once daily. After 30 days, the dose should be increased to a maintenance dose of 4 mg once daily. If additional glycemic control is needed after at least 30 days on the 4 mg dose, the dose can be increased to a maintenance dose of 9 mg once daily. This regimen is intended to mitigate gastrointestinal symptoms during dose escalation. The maximum recommended single daily dose of oral semaglutide is 9 mg. Rybelsus® must be taken on an empty stomach at least 30 minutes before the first food, beverage or other oral medications of the day. Waiting less than 30 minutes is likely to decrease the amount of semaglutide absorbed. Rybelsus® should be taken with no more than half a glass of water equivalent to 120 mL. A larger volume of water is likely to decrease the amount of semaglutide absorbed. Rybelsus® should be swallowed whole. Do not split, crush or chew. Missed Dose: If a dose is missed, the missed dose should be skipped, and the next dose should be taken the following day.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Rybelsus® is contraindicated in patients who are hypersensitive to Rybelsus® or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. Rybelsus® is contraindicated in patients who have a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Rybelsus® should not be used during pregnancy or breastfeeding.
Warnings and precautions
Risk of Thyroid C-cell Tumours: Semaglutide causes treatment-dependent thyroid C-cell tumours at clinically relevant exposures in both genders of rats and mice. It is unknown whether semaglutide causes thyroid C-cell tumours, including medullary thyroid carcinoma (MTC), in humans. Rybelsus® is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be counseled regarding the risk and symptoms of thyroid tumours. General: Rybelsus® should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Not recommended in patients with congestive heart failure NYHA class IV. Pulmonary aspiration: Cases of pulmonary aspiration have been reported in patients receiving GLP-1 receptor agonists undergoing general anaesthesia or deep sedation due to delayed gastric emptying. Sodium Content: Contains 23 mg sodium per tablet, equivalent to 1% of the WHO recommended maximum daily intake. Cardiovascular: Semaglutide causes an increase in heart rate. Caution should be observed in patients who have cardiac conditions that might be worsened by an increase in heart rate, such as tachyarrhythmias. Semaglutide causes a prolongation of the PR interval of the electrocardiogram. Caution should be observed in patients with pre-existing conduction system abnormalities or a history of rhythm disturbances. Hypoglycemia: Increased risk when used in combination with insulin secretagogues or insulin. Dose reduction of secretagogue or insulin may be needed. Gastrointestinal: May be associated with severe gastrointestinal disease (ileus). Mild-moderate GI events (nausea, diarrhea, vomiting) occurred more frequently than placebo. Pancreatic: Acute pancreatitis has been observed. Patients should be informed of symptoms. Discontinue if pancreatitis is suspected and do not restart if confirmed. Acute Gall Bladder Disease: Acute events such as cholelithiasis or cholecystitis have been reported. Patients should be informed of symptoms and evaluated if suspected. Hypersensitivity: Serious hypersensitivity reactions, including anaphylaxis, may occur. Discontinue and seek medical advice if a reaction occurs. Do not use in patients with a previous hypersensitivity to Rybelsus®.
Is Semaglutide in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by DR REDDY'S LABORATORIES LTD (Tier 3 Drug Shortages About & Resources), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 17 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| OZEMPIC | 1.34 MG | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | 02471469 |
| OZEMPIC | 0.68 MG | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | 02540258 |
| RYBELSUS | 3 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | 02497581 |
| RYBELSUS | 9 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | 02551039 |
| RYBELSUS | 14 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | 02497611 |
| RYBELSUS | 4 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | 02551020 |
| RYBELSUS | 1.5 MG | TABLET | NOVO NORDISK CANADA INC | MARKETED | 02551012 |
| WEGOVY | 4 MG / 3 ML | SOLUTION | NOVO NORDISK CANADA INC | MARKETED | 02528525 |
| OZEMPIC | 1.34 MG | SOLUTION | NOVO NORDISK CANADA INC | DORMANT | 02471477 |
| OZEMPIC | 2.68 MG | SOLUTION | NOVO NORDISK CANADA INC | APPROVED | 02523930 |
2 · Same class — other molecules in ATC A10BJ
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Semaglutide | OZEMPIC · RYBELSUS · WEGOVY | 17 | 9 | Yes |
| Dulaglutide | TRULICITY | 6 | 2 | Yes |
| Liraglutide | SAXENDA · VICTOZA | 2 | 2 | Yes |
| Exenatide | BYDUREON · BYDUREON BCISE · BYETTA | 4 | 0 | Not in Canada |
| Lixisenatide | ADLYXINE | 3 | 0 | Not in Canada |
| Albiglutide | EPERZAN | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC A10B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| A10BD | Combinations Of Oral Blood Glucose Lowering Drugs · Glimepiride And Rosiglitazone · Linagliptin And Empagliflozin · Metformin And Alogliptin · Metformin And Canagliflozin · +8 more | 123 | 67 |
| A10BH | Alogliptin · Linagliptin · Saxagliptin · Sitagliptin | 91 | 63 |
| A10BA | Metformin | 122 | 45 |
| A10BX | Nateglinide · Repaglinide · Tirzepatide | 54 | 30 |
| A10BK | Canagliflozin · Dapagliflozin · Empagliflozin · Ertugliflozin | 42 | 30 |
| A10BB | Acetohexamide · Chlorpropamide · Glibenclamide · Gliclazide · Glimepiride · +1 more | 112 | 23 |
| A10BG | Pioglitazone · Rosiglitazone | 98 | 15 |
| A10BF | Acarbose | 6 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is RYBELSUS called?
Also recorded in Canada as: 0.25 MG, 0.5 MG Dose 1.5 ML semaglutide 1.34 MG/ML Pen Injector [Ozempic] (US), semaglutide 14 MG Oral Tablet [Rybelsus] (US), semaglutide 3 MG Oral Tablet [Rybelsus] (US), semaglutide 7 MG Oral Tablet [Rybelsus] (US), 3 ML semaglutide 1.34 MG/ML Pen Injector [Ozempic] (US), 0.5 ML semaglutide 0.5 MG/ML Auto-Injector [Wegovy] (US), 0.5 ML semaglutide 1 MG/ML Auto-Injector [Wegovy] (US), 0.5 ML semaglutide 2 MG/ML Auto-Injector [Wegovy] (US), 0.75 ML semaglutide 2.27 MG/ML Auto-Injector [Wegovy] (US), 0.75 ML semaglutide 3.2 MG/ML Auto-Injector [Wegovy] (US), 3 ML semaglutide 2.68 MG/ML Pen Injector [Ozempic] (US), 0.25 MG, 0.5 MG Dose 3 ML semaglutide 0.68 MG/ML Pen Injector [Ozempic] (US), semaglutide 1.5 MG Oral Tablet [Rybelsus] (US), semaglutide 4 MG Oral Tablet [Rybelsus] (US), semaglutide 9 MG Oral Tablet [Rybelsus] (US).
The same molecule, Semaglutide, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Ozempic | Latin | Australia, Bahrain, Czechia, Iceland, Saudi Arabia, South Africa |
| Wegovy | Latin | Iceland, Saudi Arabia |
| Tasylev | Latin | Saudi Arabia |
| Ozempic (Abacus Medicine) | Latin | Iceland |
| Extensior | Latin | South Africa |
| Glucentra | Latin | Saudi Arabia |
| Lugyda | Latin | Saudi Arabia |
| Semagard | Latin | South Africa |
| Ozempic (Lyfjaver) | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.